Olivier te Boekhorst Biography and Net Worth

President and Chief Executive Officer, Director of ImmuCell

Mr. te Boekhorst was appointed President, Chief Executive Officer, and Director of ImmuCell in November 2025. He brings over 25 years of leadership experience in animal health. Before joining ImmuCell, he served as an Operating Partner at ARCHIMED, a global healthcare investment firm where he focused on animal health investments and served as Chief Executive Officer and Chairman of a portfolio company. Prior to that, Mr. te Boekhorst was at IDEXX (NASDAQ: IDXX) from 2004 to 2022. He led IDEXX’s strategy and M&A activities from 2004 to 2008 and was the Senior Vice President and General Manager of IDEXX’s livestock and dairy antibiotic residue businesses, expanding innovation for producers worldwide and advancing solutions to support animal health and food safety. Earlier in his career, he worked at The Boston Consulting Group. He serves as a Trustee of the Portland Symphony Orchestra and as a Director of PortTIX and previously served on the Board of Portland Ovations. Mr. te Boekhorst holds a bachelor’s degree from Bard College and an MBA from Cornell University.

What is Olivier te Boekhorst's net worth?: The estimated net worth of Olivier te Boekhorst is at least $176.61 thousand as of June 18th, 2026. Mr. te Boekhorst owns 17,785 shares of ImmuCell stock worth more than $176,605 as of September 17th. This net worth estimate does not reflect any other investments that Mr. te Boekhorst may own. Learn More about Olivier te Boekhorst's net worth.
How do I contact Olivier te Boekhorst?: The corporate mailing address for Mr. te Boekhorst and other ImmuCell executives is 56 EVERGREEN DR, PORTLAND ME, 04103. ImmuCell can also be reached via phone at (207) 878-2770 and via email at [email protected]. Learn More on Olivier te Boekhorst's contact information.
Has Olivier te Boekhorst been buying or selling shares of ImmuCell?: Olivier te Boekhorst has not been actively trading shares of ImmuCell in the last ninety days. Most recently, on Thursday, June 18th, Olivier te Boekhorst bought 8,000 shares of ImmuCell stock. The stock was acquired at an average cost of $9.49 per share, with a total value of $75,920.00. Following the completion of the transaction, the chief executive officer now directly owns 17,785 shares of the company's stock, valued at $168,779.65. Learn More on Olivier te Boekhorst's trading history.
Are insiders buying or selling shares of ImmuCell?: During the last year, ImmuCell insiders bought shares 2 times. They purchased a total of 9,633 shares worth more than $83,693.08. The most recent insider tranaction occured on June, 18th when CEO Olivier te Boekhorst bought 8,000 shares worth more than $75,920.00. Insiders at ImmuCell own 5.7% of the company. Learn More about insider trades at ImmuCell.
Information on this page was last updated on 6/18/2026.

Olivier te Boekhorst Insider Trading History at ImmuCell

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/18/2026	Buy	8,000	$9.49	$75,920.00	17,785

Olivier te Boekhorst Buying and Selling Activity at ImmuCell

ImmuCell Company Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Today's Range

Now: $9.97

$9.56

$9.90

50 Day Range

MA: $10.51

$9.58

$11.72

2 Week Range

Now: $9.97

$4.52

$12.10

Volume

32,613 shs

Average Volume

24,720 shs

Market Capitalization

$90.48 million

P/E Ratio

125.14

Dividend Yield

N/A

Beta

0.54